Philip Morris acquires cardiopulmonary pharmaceutical company: The healthcare hero we need, not the one we deserve

August 19, 2021 | Case Study

Philip Morris International (PMI), a wildly successful tobacco product manufacturer, has acquired inhaled therapeutics company OtiTopic. OtiTopic develops an inhaler-based therapeutic for treating heart attacks quickly. Essentially, the company aerosolizes salicylic acid (aspirin) in order to get it into the bloodstream faster, which can reduce the physical damage of a heart attack and reduce the risk of another serious event, such as a stroke. As a result of this acquisition and a slate of other reported similar acquisitions in the works, health charities and politicians are up in arms to prevent a tobacco company from pivoting into health. On the surface, it makes sense – why should a company profit from a healthcare product when it has been doing the exact opposite of providing healthcare for nearly two centuries?

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978